These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Legros V; Denolly S; Vogrig M; Boson B; Siret E; Rigaill J; Pillet S; Grattard F; Gonzalo S; Verhoeven P; Allatif O; Berthelot P; Pélissier C; Thiery G; Botelho-Nevers E; Millet G; Morel J; Paul S; Walzer T; Cosset FL; Bourlet T; Pozzetto B Cell Mol Immunol; 2021 Feb; 18(2):318-327. PubMed ID: 33408342 [TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. Wu J; Liang B; Chen C; Wang H; Fang Y; Shen S; Yang X; Wang B; Chen L; Chen Q; Wu Y; Liu J; Yang X; Li W; Zhu B; Zhou W; Wang H; Li S; Lu S; Liu D; Li H; Krawczyk A; Lu M; Yang D; Deng F; Dittmer U; Trilling M; Zheng X Nat Commun; 2021 Mar; 12(1):1813. PubMed ID: 33753738 [TBL] [Abstract][Full Text] [Related]
10. Development of neutralizing antibody responses against SARS-CoV-2 in COVID-19 patients. Teresa Valenzuela M; Urquidi C; Rodriguez N; Castillo L; Fernández J; Ramírez E J Med Virol; 2021 Jul; 93(7):4334-4341. PubMed ID: 33713457 [TBL] [Abstract][Full Text] [Related]
11. Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy. Gontu A; Srinivasan S; Salazar E; Nair MS; Nissly RH; Greenawalt D; Bird IM; Herzog CM; Ferrari MJ; Poojary I; Katani R; Lindner SE; Minns AM; Rossi R; Christensen PA; Castillo B; Chen J; Eagar TN; Yi X; Zhao P; Leveque C; Olsen RJ; Bernard DW; Gollihar J; Kuchipudi SV; Musser JM; Kapur V Commun Biol; 2021 Feb; 4(1):267. PubMed ID: 33627795 [TBL] [Abstract][Full Text] [Related]
12. The kinetics of humoral response and its relationship with the disease severity in COVID-19. Ren L; Zhang L; Chang D; Wang J; Hu Y; Chen H; Guo L; Wu C; Wang C; Wang Y; Wang Y; Wang G; Yang S; Dela Cruz CS; Sharma L; Wang L; Zhang D; Wang J Commun Biol; 2020 Dec; 3(1):780. PubMed ID: 33311543 [TBL] [Abstract][Full Text] [Related]
13. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Seow J; Graham C; Merrick B; Acors S; Pickering S; Steel KJA; Hemmings O; O'Byrne A; Kouphou N; Galao RP; Betancor G; Wilson HD; Signell AW; Winstone H; Kerridge C; Huettner I; Jimenez-Guardeño JM; Lista MJ; Temperton N; Snell LB; Bisnauthsing K; Moore A; Green A; Martinez L; Stokes B; Honey J; Izquierdo-Barras A; Arbane G; Patel A; Tan MKI; O'Connell L; O'Hara G; MacMahon E; Douthwaite S; Nebbia G; Batra R; Martinez-Nunez R; Shankar-Hari M; Edgeworth JD; Neil SJD; Malim MH; Doores KJ Nat Microbiol; 2020 Dec; 5(12):1598-1607. PubMed ID: 33106674 [TBL] [Abstract][Full Text] [Related]
14. Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients. Varnaitė R; García M; Glans H; Maleki KT; Sandberg JT; Tynell J; Christ W; Lagerqvist N; Asgeirsson H; Ljunggren HG; Ahlén G; Frelin L; Sällberg M; Blom K; Klingström J; Gredmark-Russ S J Immunol; 2020 Nov; 205(9):2437-2446. PubMed ID: 32878912 [TBL] [Abstract][Full Text] [Related]
15. A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2. Majdoubi A; Michalski C; O'Connell SE; Dada S; Narpala S; Gelinas J; Mehta D; Cheung C; Winkler DF; Basappa M; Liu AC; Görges M; Barakauskas VE; Irvine M; Mehalko J; Esposito D; Sekirov I; Jassem AN; Goldfarb DM; Pelech S; Douek DC; McDermott AB; Lavoie PM JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33720905 [TBL] [Abstract][Full Text] [Related]
16. Titers of Neutralizing Antibodies against SARS-CoV-2 Are Independent of Symptoms of Non-Severe COVID-19 in Young Adults. Jonsdottir HR; Bielecki M; Siegrist D; Buehrer TW; Züst R; Deuel JW Viruses; 2021 Feb; 13(2):. PubMed ID: 33673067 [TBL] [Abstract][Full Text] [Related]
17. Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients. Tang J; Ravichandran S; Lee Y; Grubbs G; Coyle EM; Klenow L; Genser H; Golding H; Khurana S Nat Commun; 2021 Feb; 12(1):1221. PubMed ID: 33619281 [TBL] [Abstract][Full Text] [Related]
18. Virological and immunological features of SARS-CoV-2-infected children who develop neutralizing antibodies. Cotugno N; Ruggiero A; Bonfante F; Petrara MR; Zicari S; Pascucci GR; Zangari P; De Ioris MA; Santilli V; Manno EC; Amodio D; Bortolami A; Pagliari M; Concato C; Linardos G; Campana A; Donà D; Giaquinto C; ; Brodin P; Rossi P; De Rossi A; Palma P Cell Rep; 2021 Mar; 34(11):108852. PubMed ID: 33730580 [TBL] [Abstract][Full Text] [Related]
19. Persisting Neutralizing Activity to SARS-CoV-2 over Months in Sera of COVID-19 Patients. Flehmig B; Schindler M; Ruetalo N; Businger R; Bayer M; Haage A; Kirchner T; Klingel K; Normann A; Pridzun L; Tougianidou D; Ranke MB Viruses; 2020 Nov; 12(12):. PubMed ID: 33260809 [TBL] [Abstract][Full Text] [Related]
20. Dynamics of neutralizing antibody responses to SARS-CoV-2 in patients with COVID-19: an observational study. Xu X; Nie S; Wang Y; Long Q; Zhu H; Zhang X; Sun J; Zeng Q; Zhao J; Liu L; Li L; Huang A; Hou J; Hou FF Signal Transduct Target Ther; 2021 May; 6(1):197. PubMed ID: 34006847 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]